Mustophoran (Fotemustine)

Fotemustine exerts its antineoplastic effect by forming chloroethyl radicals that alkylate DNA at the O6‑guanine position. This creates cross‑links that block DNA replication and transcription, leading to apoptosis of rapidly dividing tumor cells. The nitrosourea structure also releases nitric oxide, contributing to its cytotoxic activity.

The dosing regimen for Mustophoran is individualized. A qualified prescriber determines the appropriate dose, schedule, and duration based on the patient’s clinical condition, tumor type, prior therapies, and laboratory parameters. Exact dosing information should be obtained from the treating oncologist or prescribing information.

Mustophoran is classified as contraindicated during pregnancy and lactation because it can cross the placenta and may cause fetal harm or be excreted in breast milk. Women of child‑bearing potential should use effective contraception, and breastfeeding should be avoided while receiving treatment.

To request Mustophoran, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and assistance with import documentation.

The primary alternative to fotemustine is temozolomide, another oral alkylating agent used for gliomas. Fotemustine is administered intravenously and often shows activity in tumors resistant to temozolomide, but it carries a higher risk of myelosuppression and requires careful monitoring. Choice of therapy depends on tumor genetics, prior treatment response and patient tolerance.

Mustophoran must be stored at 2‑8 °C in a refrigerator. Keep the vial in its original packaging, protect it from light, and do not freeze or shake the solution. Before use, allow the product to reach room temperature if required, and follow aseptic techniques for preparation and intravenous administration.

Mustophoran is supplied as a sterile solution for injection and is given by intravenous infusion under the supervision of a qualified healthcare professional. The infusion rate and total volume are determined by the prescribing physician, and patients are monitored for infusion‑related reactions and hematologic parameters throughout the treatment course.

The most serious adverse events include severe myelosuppression (especially neutropenia and thrombocytopenia), pulmonary fibrosis, hemorrhagic cystitis, opportunistic infections, and rare but life‑threatening hypersensitivity reactions. Patients should be educated to report signs of infection, respiratory difficulty, blood in urine, or any unexpected allergic symptoms immediately.

Mustophoran is contraindicated in patients with known hypersensitivity to fotemustine or other nitrosoureas, in pregnant or breastfeeding women, and in individuals with severe bone‑marrow failure or uncontrolled infections. Caution is also advised for patients with significant hepatic or renal impairment, and those receiving other myelosuppressive therapies.